Akebia Therapeutics' IPO

Akebia Therapeutics raised a round of funding on March 21, 2014. Investors include Public.

Akebia Therapeutics is focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia's lead product candidate, vadadustat, is an inv…

Articles about Akebia Therapeutics' IPO: